FDA approved a premarket approval supplement application for Novocure’s second generation Optune system. The Tumor Treating Fields delivery system is now available to glioblastoma patients in the U.S. The new model features a generator that is less than half the weight and half the size of the generator in the first generation system. Additional improvements...
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
